April 21, 2016

Verseon Corporation (“Verseon” or the “Company”)

Verseon Corporation, (AIM:VSN) confirms that all resolutions put to shareholders at the Company’s Annual General Meeting held on 20 April 2016 at 14:00 PDT (22:00 BST) were duly passed.


For further information

Verseon Corporation +1 (510) 225 9000
Arthur Shmurun / Amy Thai  
Cenkos Securities (NOMAD and Broker) +44 (0) 20 7397 8900
Christopher Golden / Mark Connelly  
Abchurch Communications Ltd (PR Advisers) +44 (0) 20 7398 7719
Jamie Hooper / Alex Shaw / Abbie Warner  

About Verseon

Verseon is a technology-based pharmaceutical company that employs its proprietary computational drug discovery platform to develop novel therapeutics for today’s challenging diseases. Verseon’s platform can consistently design novel drugs that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has three active drug programs in the areas of anticoagulation, diabetic macular edema, and solid tumor cancers.

Our pledge

Verseon is committed to growth through innovation, building value for its shareholders while respecting its responsibilities as a good corporate citizen